

Form PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 018733-1055		SERIAL NO. 09/924,103	
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT		David M. GOLDENBERG, et al.			
		FILING DATE		GROUP ART UNIT		08/08/2001	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
OIPER FEB 07 2002 PATENT & TRADEMARK OFFICE							RECEIVED
							FEB 11 2002
							TECH CENTER 1600/2900
FOREIGN PATENT DOCUMENTS							
	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES NO
CY	A1	2,279,474	01/31/2000	Canada			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
CY	A2	P. Caron et al., "Supersaturating Infusional Humanized Anti-CD33 Monoclonal Antibody HuM195 in Myelogenous Leukemia 1," <u>Clinical Cancer Research</u> , Vol. 4, pgs. 1421-1428, June 1998.					
CY	A3	H. Hansen et al., "Characterization of Second-Generation Monoclonal Antibodies Against Carcinoembryonic Antigen," <u>Cancer</u> , Vol. 71, No. 11, pgs. 3478-3485, June 1993.					
CY	A4	J. Kotzerke et al., "Use of Re-188-Labeled Anti NCA-95 Antibodies in Treatment of Leukemia: First Results," <u>Journal of Nuclear Medicine</u> , Vol. 40, No. 5, May 1999, Abstract.					
CY	A5	R. Di Noto et al., "In Vitro Treatment of APL Cells with Arsenic Trioxide (As ₂ O ₃) Results in a Highly Specific Induction of Solitary CD66c Display," <u>Blood</u> , Vol. 90, No. 10, November 1997, Abstract.					
EXAMINER <i>Christopher H Y</i>		DATE CONSIDERED <i>2-12-03</i>					
		* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.					